Selexipag

Selexipag
Names
IUPAC name
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide
Other names
ACT-293987, NS-304
Identifiers
475086-01-2 YesY
3D model (Jmol) Interactive image
ChEBI CHEBI:90844 YesY
ChEMBL ChEMBL238804 N
ChemSpider 8089417 YesY
ECHA InfoCard 100.237.916
7552
KEGG D09994 YesY
PubChem 9913767
UNII P7T269PR6S YesY
Properties
C26H32N4O4S
Molar mass 496.6 g·mol−1
Pharmacology
B01AC27 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.[1]

ACT-333679 or MRE-269, the active metabolite of selexipag

History

The US FDA granted selexipag Orphan Drug status for PAH.[2] It was approved by the US FDA on 22 December 2015.[2] The expected price for the drug in the US is $160,000 to $170,000 per patient before rebates.[3]

See also

References

  1. Sitbon, O.; Morrell, N. (2012). "Pathways in pulmonary arterial hypertension: The future is here". European Respiratory Review. 21 (126): 321–327. doi:10.1183/09059180.00004812. PMID 23204120.
  2. 1 2 New Drug Approved for Rare Lung Disorder. PPN. 23 Dec 2015 Has link to GRIPHON study results
  3. "Actelion sees Uptravi price of $160,000-170,000/patient". Reuters. 2016-01-05. Retrieved 2016-01-06.


This article is issued from Wikipedia - version of the 1/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.